Skip to main content

Table 3 Changes in proportions of subsets and surface markers of B cells, natural killer cells and monocytes during tocilizumab treatment

From: Peripheral blood CD4+CD25+CD127low regulatory T cells are significantly increased by tocilizumab treatment in patients with rheumatoid arthritis: increase in regulatory T cells correlates with clinical response

Subsets and surface markers Median (interquartile range) Baseline vs. week 52
  Baseline Week 24 Week 52 P -value
B cells/lymphocytes 3.2 (2 to 5.1) 4.1 (3.1 to 5.2) 4.1 (3.1 to 5.2) 0.118
CD80+ B cells/B cells 26.9 (13.5 to 32) 19.3 (12.4 to 26.3) 19.3 (13.2 to 21.4) 0.045*
CD86+ B cells/B cells 42.5 (36.5 to 47.6) 34 (29.2 to 38.1) 36.7 (32.1 to 41.9) 0.009*
HLA-DR+ B cells/B cells 99.6 (99 to 99.8) 99.4 (98.8 to 99.8) 99.5 (99.3 to 99.8) 0.833
Naïve B cells/B cells 52 (43.1 to 60.3) 62.7 (52.7 to 68.2) 66.7 (57.6 to 74.6) <0.001*
Memory B cells/B cells 48 (39.7 to 56.9) 37.3 (31.8 to 47.3) 33.3 (25.4 to 42.4) <0.001*
NK cells/lymphocytes 24.1 (20.0 to 27.5) 25.8 (21.2 to 30.5) 24.5 (20.9 to 29.5) 0.401
CD80+CD14+ monocytes/CD14+ monocytes 0.2 (0.1 to 0.3) 0.2 (0.1 to 0.3) 0.2 (0.1 to 0.3) 0.433
CD86+CD14+ monocytes/CD14+ monocytes 99.6 (99.2 to 99.9) 99.7 (99.3 to 99.9) 99.8 (99.6 to 99.9) 0.054
HLA-DR+CD14+ monocytes/CD14+ monocytes 99.5 (89.3 to 99.8) 98.2 (89.7 to 99.6) 94.6 (86 to 95.8) 0.004*
CD69+CD14+ monocytes/CD14+ monocytes 66.7 (60.6 to 74.8) 48.3 (35.8 to 70.1) 34 (26.2 to 56.9) <0.001*
CD16+CD14+ monocytes/CD14+ monocytes 16 (10.3 to 20.9) 8.6 (4.5 to 12.6) 8.1 (3.8 to 12.9) <0.001*
CD16CD14+ monocytes/CD14+ monocytes 84 (79.1 to 89.7) 91.4 (87.4 to 95.5) 91.9 (87.1 to 96.2) <0.001*
  1. *Significant differences using Wilcoxon’s matched-pairs signed-rank test.
\